- Target disease: Visceral leishmaniasis (VL)
- Main partners (since project start): Takeda Pharmaceutical Company Ltd., Japan
- Project start: 2017
- Funding (since project start): Department for International Development (DFID), UK; Global Health Innovative Technology (GHIT) Fund, Japan.
This project is the continuation of the optimization of the aminopyrazole series for visceral leishmaniasis project. DNDi and Takeda worked with the objective of delivering an anti-parasitic aminopyrazole drug that could meet the Target Product Profile (TPP) published by DNDi. A lead second generation compound DNDI-5561 and several additional advanced, and differentiated, second generation leads have been identified that could provide differentiated back-ups. DNDI-5561 is the most advanced compound of the aminopyrazole series.
The pre-clinical trial application package studies to enable a first-in-human study (Phase I) should start early 2019 and should be completed by the end of 2019.
Following positive results of efficacy and safety studies in animal model, DNDI-5561 was selected as pre-clinical candidate in October 2017.
Last update: February 2019